Key Inclusion Criteria - Patients must meet all of the inclusion criteria to be eligible
        for enrollment into the study:

          -  Histologically confirmed diagnosis of locally advanced, unresectable or metastatic
             cutaneous melanoma or unknown primary melanoma American Joint Committee on Cancer
             (AJCC) Stage IIIB, IIIC or IV; or other BRAF V600-mutant advanced solid tumors

          -  Presence of BRAF V600E and/or V600K mutation in tumor tissue prior to enrollment, as
             determined using a local test;

          -  Evidence of measurable or non-measurable lesions

          -  Patient with unresectable locally advanced or metastatic melanoma who has received no
             prior treatment or progressed on or after prior systemic therapy; Note: Prior therapy
             with a BRAF proto-oncogene serine-threonine protein kinase (BRAF) inhibitor and/or a
             mitogen-activated protein (MAP) kinase (MEK) inhibitor is permitted except in the
             regimen immediately prior to study entry

          -  Patient with other (non-melanoma) BRAF V600E and/or V600K -mutant advanced solid
             tumors who has progressed on standard therapy or for whom there are no available
             standard therapies; Note: Prior therapy with a BRAF inhibitor and/or a MEK inhibitor
             is permitted except in the regimen immediately prior to study entry

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Adequate bone marrow, hepatic and renal function as specified in the protocol

          -  ARM 1 ONLY: Non-smoker who has not used nicotine containing products for at least 3
             months prior to the first dose.

        Key Exclusion Criteria - Patients meeting any of the following criteria are not eligible
        for enrollment in the study:

          -  Symptomatic brain metastasis. Patients previously treated or untreated for these
             conditions that are asymptomatic in the absence of corticosteroid and anti-epileptic
             therapy are allowed. Brain metastases must be stable, with imaging (e.g., magnetic
             resonance imaging [MRI] or computed tomography [CT] demonstrating no current evidence
             of progressive brain metastases at screening);

          -  Symptomatic or untreated leptomeningeal disease;

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity
             or hypercoagulability syndromes);

          -  Clinically significant cardiac disease

          -  Known hyper-coagulability risks other than malignancy (e.g., Factor V Leiden
             syndrome);

          -  Thromboembolic event except catheter-related venous thrombosis ≤ 12 weeks prior to
             starting study treatment.

          -  Discontinuation of prior BRAF and/or MEK inhibitor treatment due to left ventricular
             dysfunction, pneumonitis/interstitial lung disease, or retinal vein occlusion;

          -  ARM 1 ONLY: Positive urine cotinine test at screening

          -  ARM 3 ONLY:

               -  History of psychosis, depression or mania;

               -  History of angioedema;

               -  History of mitral valve prolapse;

               -  History of left ventricular hypertrophy;